What exactly is radiotheranostics, and why does it matter for patients?

 

Our team, Alice F. Viana and Elisa Cannarozzo, co-authored a clear guide in the Journal of Nuclear Medicine to explain it in plain language. The article unpacks the idea at the heart of our work: “see what you treat, and treat what you see.” The same type of molecule can either reveal cancer cells on a scan or deliver treatment directly to them, depending on the radioactive element it carries.

 

How it works, simply: a radiopharmaceutical combines a ligand that recognises specific markers on cancer cells with a radioisotope. It travels through the body, binds to its target, and then either lights up on imaging or delivers a precise dose to the tumour, while largely sparing healthy tissue.

 

Why it matters for patients:

 

• Personalization: imaging first confirms the tumour carries the target, so therapy is given when it’s likely to work.
• Precision: radiation is delivered directly to cancer sites, limiting exposure elsewhere.
• Real-time monitoring: the care team can see how treatment is working over time.

 

Used today in cancers such as neuroendocrine tumours, prostate and thyroid, and being studied in others, theranostics is one of the most promising directions in modern cancer care. Making it understood is part of our mission: because innovation only counts when it reaches people.